Author Archive: BIOtechNOW Editor

Inter Partes Review – a Useful Tool for Overcoming Freedom-to-Operate Obstacles

Basic CMYK

By Eric K. Steffe, Eldora L. Ellison, Ph.D., Todd Spalding, and Deborah A. Sterling, Ph.D. For companies facing freedom-to-operate obstacles, the AIA provides a number of tools for dealing with troublesome patents.  While proceeding at risk in the face of such patents sometimes make sense, inter partes review (IPR) provides a viable option for challenging them and should be considered as a valuable addition to one’s freedom-to-operate toolbox. Inter partes reexamination (IPX), which (bio)pharma used Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

Academics to be Featured at the 2013 BIO Alliance Pavilion

BIO International Convention

I think it safe to say that the U.S. biotechnology industry has its R&D roots in the laboratories of great research universities with great science and visionary researchers. These cutting-edge, biology-based research and industry commercialization efforts continue to be the key drivers in moving invention into innovation to heal, fuel and feed the world. Because of this essential knowledge-driven relationship, the 2013 BIO International Convention will again bring together academic and research colleagues to focus Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

SIPO Examiner Workshop: Biotech Patent Practices in the U.S., China and Japan

Great Wall of China - Image by jrover

The biotechnology industry is an invention-intensive industry that relies heavily on the protection of intellectual property, especially patent rights. Patent protection is territorial, and patent practice varies in different jurisdictions. Many foreign biotech companies continue to look at China as an important emerging market, and they increasingly file patent applications in China to develop their global patent portfolios. At the same time, China has made biotechnology one of the eight strategic new technology focuses in Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

It’s World Polio Day – Time to Make History

John Hewko

Oct. 24 is World Polio Day, an opportunity to share a message of extreme importance: The global community must step up now with the resources needed to eradicate this crippling childhood disease once and for all. In all of history, smallpox is the only human disease to be eradicated. It’s time to make global health history a second time by wiping out polio. And that can only happen by reaching every child in every corner Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , ,

Pharma & Biotech Companies Donate Hundreds of Millions of Dollars to Copayment Foundations. Here’s Why.

Mary Sundeen

In addition to using their own Patient Assistance Programs, many pharma and biotech companies are supporting independent 501(c)3 non-profit copayment foundations to increase treatment compliance, access to care for insured Americans (including Medicare patients), and to promote proper disease management. Copayment foundations have helped hundreds of thousands of insured Americans afford their coverage and their treatments. The HealthWell Foundation, one of the nation’s largest non-profits, recently issued a white paper on copayment assistance as a Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,